Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963338 | 0.94 | MMP8 (0.43) | MMP8ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL13020529 | 0.88 | MMP8 (0.45) | MMP8ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL13765460 | 0.88 | MEN1 (0.32) | MMP8ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL13130096 | 0.84 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL13134451 | 0.84 | ALDH1A1 (0.36) | MMP8ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL13020436 | 0.84 | MMP8 (0.40) | MMP8MEN1KMT2APKMKDM4E | |
| SCHEMBL2319226 | 0.82 | MMP8 (0.51) | MMP8ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL2809869 | 0.81 | ALDH1A1 (0.45) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL13064101 | 0.81 | MMP8 (0.47) | MMP8ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL13020446 | 0.79 | MMP8 (0.41) | MMP8ALDH1A1LMNAHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160331770-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2016-11-17 | — | — | US | disclosed |
| US-9441007-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150315228-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9073960-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | MMP8 2798/4885ALDH1A1 3576/4885LMNA 961/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | MMP8 1799/4885ALDH1A1 1153/4885LMNA 1356/4885 |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | MMP8 229/4885ALDH1A1 1405/4885LMNA 822/4885 |
| US-20160331770-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | MMP8 2798/4885ALDH1A1 3576/4885LMNA 961/4885 |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | MMP8 2798/4885ALDH1A1 3576/4885LMNA 961/4885 |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | PNP, NTPCR, TYMP | MMP8 2432/4885ALDH1A1 3343/4885LMNA 1360/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | MMP8 2272/4885ALDH1A1 2902/4885LMNA 1477/4885 |
| US-20150315228-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | MMP8 2798/4885ALDH1A1 3576/4885LMNA 961/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | MMP8 1799/4885ALDH1A1 1153/4885LMNA 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.